Gamma-globulin modulates growth of EBV-derived B-cell tumors in scid mice reconstituted with human lymphocytes
✍ Scribed by Mohammad R. Abedi; Birger Christensson; Salahuddin Al-Masud; Lennart Hammarström; C. I. Smith
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- French
- Weight
- 717 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The effect of weekly y-globulin injection on the development of human B-cell tumors was studied in I20 mice with severe combined immunodeficiency (SCID). The mice were injected intraperitoneally (Lp.) with human peripheral mononuclear cells (PBMC) from 6 different Epstein-Barr virus (EBV)seropositive donors. Animals repopulated with cells from 5 donors received y-globulin or saline for 20 weeks and were followed up to 24 weeks after reconstitution. A delay in the appearance of fatal EBV-derived human B-cell tumors was noticed in the yglobulin-treated groups as compared to the controls. In a separate experiment, the effect of y-globulin treatment during the initial 4 weeks after reconstitution was compared to treatment from week 5 to week 8 as well as to a continuous 20-week treatment. The results from this experiment showed that B-cell tumor growth could be prevented just as efficiently when the animals were treated only during the first 4 weeks. In contrast, no preventive effect was seen when the first y-globulin dose was given at the beginning of week 5 after reconstitution. Our results indicate that yglobulin reduces the frequency of EBV-derived B-cell tumor development and suggest that SCID mice repopulated with human cells represent a useful in vivo model for evaluation of the prophylactic and/or therapeutic effects of immunomodulatory treatments in lymphoproliferative disorders associated with immunosuppression.